Botox vs. Xeomin: The “Naked Toxin” Compared to the Gold Standard (2026 Guide)

If you are weighing Botox against Xeomin for frown lines, forehead creases, or crow’s feet, the most interesting clinical difference between the two is what is not in the Xeomin vial. Xeomin is the only FDA-approved cosmetic neuromodulator manufactured without the accessory complexing proteins included in every other product in the category. This is the basis for its “naked toxin” marketing and a real-but-modest theoretical advantage on long-term antibody risk.

This guide walks through every meaningful difference between Botox and Xeomin based on the current FDA labels and the head-to-head literature. Because Xeomin is not part of our menu, this guide is written to help you choose on the merits, and to point you toward the Naya-carried alternative if Xeomin is hard to access.

What Botox and Xeomin Actually Are

Both are purified type A botulinum toxin. Both block acetylcholine release at the neuromuscular junction, which silences the targeted facial muscle and smooths the overlying dynamic wrinkle.

Where they diverge — and it is the entire formulation story for Xeomin:

• Botox (onabotulinumtoxinA) — made by Allergan Aesthetics (an AbbVie company), FDA-approved for cosmetic glabellar lines in 2002 and for forehead lines and crow’s feet in subsequent years. Formulated with a roughly 900 kDa accessory-protein complex and human serum albumin as a stabilizer.
• Xeomin (incobotulinumtoxinA) — made by Merz Aesthetics, FDA-approved for cosmetic glabellar lines in 2011. Formulated as the 150 kDa active toxin alone, with no accessory complexing proteins. Merz markets this as the “naked toxin” or “uncomplexed” formulation. Human serum albumin is not present as an accompanying excipient in the way it is in the complex-containing products.

The reason this matters: accessory complexing proteins are foreign proteins. In theory, repeated exposure over many years could prompt antibodies that neutralize the active toxin and reduce future effectiveness. In practice, the absolute incidence of clinically meaningful neutralizing antibodies at cosmetic doses is very low for all FDA-approved type A products. The Xeomin pitch is that the absence of complexing proteins lowers that theoretical risk further — most relevant for patients treated continuously for many years or with specific antibody concerns.

Onset: When Will You See Results?

This is one area where Botox is modestly faster than Xeomin on average.

• Botox onset: Most patients see softening at 3–7 days, with peak effect at roughly 10–14 days.
• Xeomin onset: Most patients see softening at 5–7 days, with peak effect at roughly 14 days.

For routine maintenance, the onset difference washes out. For a time-pressed event in 5–10 days, Botox’s slight head start matters. This is unusual: most Botox alternatives (Dysport, Letybo, Jeuveau, Daxxify) are modestly faster to onset, while Xeomin is the one that runs slightly slower.

Duration: How Long Will Results Last?

Duration is essentially the same between the two.

• Botox: 3–4 months for glabellar lines; FDA label specifies re-treatment no more frequent than every 3 months.
• Xeomin: Also 3–4 months. Head-to-head literature against onabotulinumtoxinA has consistently shown comparable duration in glabellar lines.

If duration is your top priority, the longer-acting FDA-approved option to discuss is Daxxify (median ~6 months). Between Botox and Xeomin, choose on formulation preference, onset, and access — not duration.

Dosing: The 1:1 Conversion

Per the FDA labels:

• Botox for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).
• Xeomin for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

The conversion is 1:1. An injector trained on Botox dosing for a given area can use the same per-area unit counts with Xeomin. FDA labels still warn that units between branded products are not formally interchangeable, so your injector should document which product was used at what dose, but the practical math is straightforward.

This 1:1 simplicity is one reason Xeomin has been an easy adjacency for Botox-fluent clinics that carry it.

Diffusion and Precision

Both Botox and Xeomin have tight, precise diffusion profiles. Xeomin behaves like Botox in terms of localization — appropriate for the same focal targets (crow’s feet, lip flips, masseters) where you do not want spread to neighboring muscle groups. The absence of complexing proteins does not meaningfully change Xeomin’s diffusion profile. Choose between these two on formulation philosophy, onset, and provider familiarity.

Cost: What You Will Actually Pay in 2026

National 2026 averages, with the caveat that prices vary by city and clinic experience:

• Botox: roughly $12–$20 per unit, with most clinics in the $14–$16 range. A standard glabellar treatment (20 units) lands around $280–$320.
• Xeomin: roughly $10–$15 per unit. A standard glabellar treatment (20 units) lands around $200–$300.

Xeomin is typically priced modestly lower than Botox — generally a 10–20% per-unit discount rather than the larger spread Letybo or Dysport offer. With 1:1 dosing, that translates to a $20–$80 gap per glabellar treatment, small enough that formulation philosophy is usually the deciding factor, not cost.

Side Effects, Safety, and the Antibody Question

The general side effect profile of Xeomin is very similar to Botox and the other type A toxins. In Merz’s phase-3 program and in head-to-head studies against onabotulinumtoxinA, the most common adverse events for Xeomin were:

• Headache (3–9%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid drooping (ptosis), uncommon in experienced hands
• Asymmetric brow position, typically correctable at a 2-week touch-up

The substantive Xeomin-specific question is the long-term antibody one. Across all FDA-approved cosmetic type A products at standard glabellar doses, clinically meaningful neutralizing-antibody development is uncommon — it is much more frequently observed at the higher therapeutic doses used for movement disorders or spasticity. For most cosmetic patients, the absolute risk reduction Xeomin offers is small in real terms even if it is real in theory. It is most relevant for patients with very long anticipated treatment horizons or those who have previously had a confirmed loss of response to a complex-containing product.

Worth noting: Daxxify also does not use human serum albumin (it uses a proprietary peptide excipient called RTP-004), so if the no-albumin angle is what drew you to Xeomin, Daxxify is another product to discuss.

Both Botox and Xeomin carry the same FDA boxed warning about the theoretical possibility of distant toxin spread; in cosmetic facial doses, this has not been a clinically meaningful concern across millions of treatments.

Who Is the Ideal Candidate for Each?

Botox may be the better fit if:

• You want the longest established US cosmetic track record
• You value a slightly faster median onset (3–7 days vs. 5–7 for Xeomin)
• Your provider has substantially more volume experience with Botox
• You are budget-flexible and prioritize provider familiarity over modest per-unit savings

Xeomin may be the better fit if:

• You specifically value the “naked toxin” formulation for theoretical antibody-risk reasons
• You anticipate a very long treatment horizon (many years of continuous dosing)
• You have had a documented loss of response to a complex-containing toxin in the past
• You prefer a formulation that does not include accessory complexing proteins, on philosophical grounds

Can You Switch Between Botox and Xeomin?

Yes. Because the two are dosed 1:1 and behave similarly, switching is straightforward. A few practical notes:

• Tell your new injector which product you previously had, the dose, and when. Even with 1:1 dosing, documentation matters.
• You cannot combine the two products in the same treatment area in the same session.
• For patients who suspect reduced Botox responsiveness over many years of treatment, switching to Xeomin is sometimes considered as a potential reset. This is uncommon and should be a discussion with an experienced provider rather than an assumption.
• Switching does not eliminate the small theoretical antibody-formation risk, but the Xeomin pitch is specifically that residual risk is lower.